On November 19, Twist Bioscience Corp rose 5.64% in Regular Trading, trading at $122.62 per share, with turnover of $49.2264 million.
The move came as the market continued to digest the company’s latest quarterly results and management’s outlook for slower AI drug discovery growth, while analyst target-price revisions remained divided and kept post-earnings positioning active.
Background context shows the company reported fiscal fourth-quarter revenue of $126.6 million and a loss of $0.32 per share, both better than consensus. Fiscal first-quarter revenue guidance of $130 million to $132 million and full-year revenue guidance of $550 million to $560 million were also slightly above expectations. Even so, management indicated slower growth in AI drug discovery-related business. Analyst reactions then split, with UBS cutting its target to $120, Jefferies to $125, and Guggenheim to $150, while Piper Sandler raised its target to $140.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments